SBBP - Strongbridge Biopharma plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Strongbridge Biopharma plc

900 Northbrook Drive
Suite 200
Trevose, PA 19053
United States
610-254-9200
http://www.strongbridgebio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees106

Key Executives

NameTitlePayExercisedYear Born
Mr. Matthew PaulsCEO, Pres & Director958.84kN/A1971
Mr. Richard S. Kollender CPA, M.B.A., CPAChief Operating Officer70kN/A1969
Dr. Fredric CohenChief Medical Officer672.45kN/A1965
Dr. Per Marin M.D., Ph.D.Founder and Sr. Clinical AdvisorN/AN/AN/A
Mr. Robert Matthew LutzChief Financial OfficerN/AN/A1969
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Corporate Governance

Strongbridge Biopharma plc’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.